SOAR Act Takes Flight: Bipartisan Push To Improve Supplemental Oxygen Access And Medicare Protections

Published in Government Relations on April 11, 2025

The Supplemental Oxygen Access Reform (SOAR) Act has been reintroduced in both the House and Senate. In the House, the bipartisan H.R. 2902 was introduced by Representatives David Valadao (R-CA), Julia Brownley (D-CA), Adrian Smith (R-NE), and Gabe Evans (R-CO). Meanwhile, in another show of bipartisan support, S1406, was introduced in the U.S. Senate by Senators Bill Cassidy (R-LA), Mark Warner (D-VA), and Amy Klobuchar (D-MN).  

According to CQRC, the SOAR Act is designed to streamline patients’ access to availability and delivery of supplemental oxygen in three impactful ways:  

  1. Establishing strong patient protections, including the establishment of a standardized, electronic template to protect patients and providers against fraud and abuse. 
  2. Creating a stable Medicare reimbursement rate to safeguard access to the proper oxygen modalities for patients, including liquid oxygen. 
  3. Recognizing the important role of respiratory therapy services with an add-on payment. 

The SOAR Act also aims to remove supplemental oxygen from Medicare’s Competitive Bid Program and establishes separate rates for liquid and non-liquid oxygen. Furthermore, it would require Medicare contractors to adopt a template created by CMS which would aim to prevent fraud and abuse while clarifying needs of the patient—ultimately ensuring fair reimbursement for providers.  

VGM is excited to collaborate and advocate with our industry partners to garner additional support from both chambers on this important piece of legislation. Together, we aim to drive meaningful change and ensure impactful legislative progress that benefits the communities we serve. We will provide updates as they become available.  

Learn more about the SOAR Act here:  

HME News: Bill introduced to ‘maintain and stabilize’ oxygen reimbursement 

CQRC: Supplemental Oxygen Providers & Suppliers Commend Reintroduction of the Supplemental Oxygen Access Reform (SOAR) Act in U.S. Congress - CQRC

From Our Experts

Proposed Rule Suggests Significant Change To Accreditation Process thumbnail Proposed Rule Suggests Significant Change To Accreditation Process The recently released proposed rule CMS-1828-P contains a significant change that could reshape how suppliers navigate accreditation. The rule proposes a major change that would require suppliers to be surveyed and reaccredited annually instead of the current three (3) year cadence. This proposal raises substantial questions about both operational feasibility and cost implications. August Of Action: Your Chance To Connect With Congress thumbnail August Of Action: Your Chance To Connect With Congress It's time to take advantage of August Of Action—a perfect opportunity to make your voice heard. Every summer, federal legislators return to their home states during the Congressional recess. While it gives them a break from Washington D.C., it's primarily a time for them to connect with constituents like you. HR1 Passes House, Advances to President Trump's Desk for Signature thumbnail HR1 Passes House, Advances to President Trump's Desk for Signature After extensive negotiations and partisan debate, the House has officially passed HR1, clearing the path for the bill to be signed into law by President Donald Trump. The legislation, which aims to reduce federal healthcare expenditures, contains several provisions that may impact the durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS) industry. CMS files the Proposed Rule that sheds light on the next round of the Competitive Bidding Program thumbnail CMS files the Proposed Rule that sheds light on the next round of the Competitive Bidding Program On June 30, 2025, CMS filed the anticipated Proposed Rule that includes updates to the Competitive Bidding Program (CBP). Public comments are due 60 days from June 30, 2025. Below is a high-level summary of the rule. It is critical to note that, according to the Proposed Rule Fact Sheet dated June 30, 2025, CMS has stated that they have not announced the specific product categories they are bidding or the specific timeframe for the next competition. Those specifics will be forthcoming in a fu Senate Narrowly Passes HR1, Sending It Back to House for Final Approval thumbnail Senate Narrowly Passes HR1, Sending It Back to House for Final Approval President Donald Trump's sweeping legislative package, formally titled the One Big, Beautiful Bill Act, now referred to as HR1., cleared the Senate today in a dramatic 51–50 vote, with Vice President JD Vance casting the tie-breaking vote. The bill now returns to the House, where lawmakers must decide whether to adopt the Senate's revised version or negotiate further changes before it can reach the president's desk. Several Prominent Medicaid Provisions in Senate's Budget Bill Deemed in Violation of Byrd Rule thumbnail Several Prominent Medicaid Provisions in Senate's Budget Bill Deemed in Violation of Byrd Rule Senate Parliamentarian Elizabeth MacDonough advised this week that multiple Medicaid provisions in the Senate's reconciliation bill would violate Senate procedure by violating the Byrd Rule. The Byrd Rule is a Senate-specific procedural process that allows Senators to prevent or block inclusion of extraneous provisions in reconciliation bills. Other provisions are still under review. Evaluating the Value of a Payer Contract thumbnail Evaluating the Value of a Payer Contract In our last article, Key Payers Denied Your Application Citing Their Network Is Closed – Now What?, we discussed strategies for addressing payer contracting denials due to a closed network. As indicated, this process can be an extremely time-consuming exercise with no guarantees and mixed results. Below are a few things to consider as you evaluate whether a contract is worth the extra effort. Webinar: Webinar: "Navigating The New CMS Landscape: RADs, HMVs, and Supplier Survival" on June 25 at 1 p.m. CT. The Centers for Medicare & Medicaid Services (CMS) has released its final National Coverage Determination (NCD) for RADs and HMVs used in treating chronic respiratory failure due to COPD. While the rule potentially expands access to bilevel ST therapy (RADs), it also introduces complex compliance requirements, tighter usage criteria, and increased documentation burdens—without additional reimbursement.